Last Updated: September 24, 2026

ZILXI Drug Patent Profile

Name: ZILXI Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Zilxi patents expire, and what generic alternatives are available?

Zilxi is a drug marketed by Journey and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ZILXI is minocycline hydrochloride. There is one drug master file entry for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zilxi

A generic version of ZILXI was approved as minocycline hydrochloride by WATSON LABS on December 30^th, 1991.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ZILXI?
What are the global sales for ZILXI?
What is Average Wholesale Price for ZILXI?

Summary for ZILXI

US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	95
Patent Applications:	2,725
Drug Prices:	Drug price information for ZILXI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZILXI
What excipients (inactive ingredients) are in ZILXI?	ZILXI excipients list
DailyMed Link:	ZILXI at DailyMed

Drug patent expirations by year for ZILXI

Pharmacology for ZILXI

Drug Class	Tetracycline-class Drug
Physiological Effect	Decreased Prothrombin Activity

Paragraph IV (Patent) Challenges for ZILXI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZILXI	Topical Aerosol Foam	minocycline hydrochloride	1.50%	213690	1	2022-02-28

US Patents and Regulatory Information for ZILXI

ZILXI is protected by ten US patents.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Journey	ZILXI	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	213690-001	May 28, 2020		RX	Yes	Yes	10,213,512	⤷ Start Trial	Y			⤷ Start Trial
Journey	ZILXI	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	213690-001	May 28, 2020		RX	Yes	Yes	12,138,311	⤷ Start Trial				⤷ Start Trial
Journey	ZILXI	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	213690-001	May 28, 2020		RX	Yes	Yes	8,865,139	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ZILXI

See the table below for patents covering ZILXI around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Australia	2010302350		⤷ Start Trial
Australia	2015224534		⤷ Start Trial
Brazil	112012007473		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.